Marlboro-based Cytyc Corp., through its Cytyc Corp. Development Co. subsidiary, is taking part in start-up investment in Combinent BioMedical Systems.
Combinent is an early stage company developing a single-device vaginal drug delivery method for a combination of drugs currently given orally and intravenously that treat hormonal disorders.
Cytyc is a medical device company that specializes in cervical cancer screening and other women’s specialty products.
Combinent was founded by doctors and chemical engineers from the Massachusetts Institute of Technology and Massachusetts General Hospital.
The company will be based in Boston.
Cytyc is funding the start-up along with VIMAC Ventures and Commons Capital.
John McDonough, Cytyc president, will have a seat on Combinent’s board of directors.
